Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blind, Active-controlled, Parallel, Phase 3 Study to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia

NCT07378098 is registered in ClinicalTrials.gov with JW Pharmaceutical as lead sponsor.

NCT NCT07378098
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07378098 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blind, Active-controlled, Parallel, Phase 3 Study to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia
Lead sponsor
JW Pharmaceutical
Phase
Phase 3
Overall status
Recruiting
Start date
February 3, 2026
Completion date
September 3, 2028
Enrollment
254 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

menorrhagia, uterine fibroids